Total Payments
$207,817
2024 Payments
$72,605
Companies
9
Transactions
63
Payment Breakdown by Category
Consulting$192,434 (92.6%)
Travel$7,896 (3.8%)
Other$5,150 (2.5%)
Food & Beverage$1,485 (0.7%)
Gifts$851.43 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $192,434 | 29 | 92.6% |
| Travel and Lodging | $7,896 | 8 | 3.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,150 | 2 | 2.5% |
| Food and Beverage | $1,485 | 23 | 0.7% |
| Gift | $851.43 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $99,322 | 22 | $0 (2024) |
| GlaxoSmithKline, LLC. | $56,034 | 24 | $0 (2021) |
| Medical Graphics Corporation | $29,450 | 6 | $0 (2022) |
| Pulmonx Corporation | $19,230 | 5 | $0 (2019) |
| Horizon Therapeutics plc | $2,567 | 2 | $0 (2022) |
| Chiesi USA, Inc. | $712.50 | 1 | $0 (2024) |
| Novartis Pharma AG | $455.00 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.00 | 1 | $0 (2023) |
| AbbVie Inc. | $14.21 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72,605 | 19 | AstraZeneca UK Limited ($71,892) |
| 2023 | $27,463 | 5 | AstraZeneca UK Limited ($27,430) |
| 2022 | $12,567 | 3 | Medical Graphics Corporation ($10,000) |
| 2021 | $15,939 | 4 | GlaxoSmithKline, LLC. ($15,925) |
| 2020 | $46,926 | 5 | GlaxoSmithKline, LLC. ($36,075) |
| 2019 | $17,209 | 23 | Medical Graphics Corporation ($8,598) |
| 2018 | $14,653 | 3 | Pulmonx Corporation ($14,653) |
| 2017 | $455.00 | 1 | Novartis Pharma AG ($455.00) |
All Payment Transactions
63 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,745.25 | General |
| 11/06/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $5,686.83 | General |
| 10/10/2024 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $712.50 | General |
| 04/16/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $13,612.95 | General |
| 03/11/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $13,779.42 | General |
| 03/11/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $7,066.92 | General |
| 02/22/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $12,082.50 | General |
| Category: Respiratory | ||||||
| 02/22/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $11,545.50 | General |
| Category: Respiratory | ||||||
| 02/22/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $4,070.46 | General |
| Category: Respiratory | ||||||
| 02/15/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | Cash or cash equivalent | $29.10 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $576.80 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $478.50 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $461.48 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $230.63 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $159.23 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $150.46 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $149.89 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $38.96 | General |
| Category: Respiratory | ||||||
| 01/12/2024 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Respiratory | ||||||
| 12/06/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $6,755.46 | General |
| Category: Respiratory | ||||||
| 10/27/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $11,545.50 | General |
| Category: Respiratory | ||||||
| 09/26/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $3,984.54 | General |
| Category: Respiratory | ||||||
| 06/14/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Consulting Fee | Cash or cash equivalent | $5,144.46 | General |
| Category: Respiratory | ||||||
| 05/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $33.00 | General |
| 10/03/2022 | Horizon Therapeutics plc | — | Consulting Fee | Cash or cash equivalent | $1,433.33 | General |
About Dr. Christopher Cooper, MD
Dr. Christopher Cooper, MD is a Pulmonary Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588680482.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Cooper, MD has received a total of $207,817 in payments from pharmaceutical and medical device companies, with $72,605 received in 2024. These payments were reported across 63 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($192,434).
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Los Angeles, CA
- Active Since 07/14/2006
- Last Updated 02/24/2014
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1588680482
Products in Payments
- BREZTRI (Drug) $57,431
- Pulmonx Endobronchial Valve EBV (Device) $19,230
- TRELEGY ELLIPTA (Drug) $4,550
- NVA237A (Drug) $455.00
- UBRELVY (Drug) $14.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Los Angeles
Prof. Toby Maher, Md, MD
Pulmonary Disease — Payments: $1.1M
Pulmonary Disease $1.1M
Donald Tashkin, Md, MD
Pulmonary Disease — Payments: $646,650
Pulmonary Disease $646,650
Rajan Saggar, Md, MD
Pulmonary Disease — Payments: $426,392
Pulmonary Disease $426,392
John Belperio, Md, MD
Pulmonary Disease — Payments: $308,808
Pulmonary Disease $308,808
Robert Strieter, Md, MD
Pulmonary Disease — Payments: $172,942
Pulmonary Disease $172,942
Roy Artal, M.d, M.D
Pulmonary Disease — Payments: $151,187
Pulmonary Disease $151,187